David Lebwohl, M.D., serves as the Executive Vice President and Chief Medical Officer at Intellia Therapeutics Inc., a leading clinical-stage genome editing company focused on developing curative therapeutics leveraging CRISPR-based technologies. Dr. Lebwohl brings a wealth of experience in the biopharmaceutical industry, having held key leadership positions at several prominent companies. Before joining Intellia, he was the Chief Medical Officer at Enzyvant Therapeutics, where he played a pivotal role in advancing the company's gene therapy programs. Prior to his tenure at Enzyvant, Dr. Lebwohl served as the Chief Medical Officer at Mesoblast Limited, a global leader in developing innovative allogeneic cellular medicines. During his time at Mesoblast, he was instrumental in overseeing the clinical development of multiple cell therapy programs, significantly contributing to the company's growth and success. Dr. Lebwohl's earlier career also includes a significant stint at Pfizer, where he held various senior roles, including Vice President of Clinical Development and Medical Affairs for Pfizer's Specialty Care Business Unit. His work at Pfizer involved leading the development and commercialization of several high-profile products across different therapeutic areas. In his current role at Intellia Therapeutics, Dr. Lebwohl is responsible for overseeing the company's clinical development strategy and execution. His leadership is crucial in advancing Intellia's pipeline of CRISPR-based therapies, which aim to provide transformative treatments for patients with genetic diseases and cancer. Dr. Lebwohl's extensive experience in clinical development, regulatory affairs, and medical affairs positions him well to guide Intellia through its next phase of growth and innovation, ensuring that the company continues to deliver on its mission to develop life-changing genetic medicines.